

Is Benicar HCT in shortage in 2026? Get the latest update on availability, pricing, and what to do if you can't find your blood pressure medication.
If you've been told your pharmacy can't fill your Benicar HCT prescription, you're probably wondering: is there a shortage? The short answer is that Benicar HCT is not on the FDA's official drug shortage list as of early 2026. But that doesn't mean every pharmacy has it on the shelf.
Drug availability is complicated. Even when there's no official nationwide shortage, you can still run into problems at your local pharmacy. Let's look at what's really going on with Benicar HCT supply in 2026 and what you can do about it.
Benicar HCT is a combination blood pressure medication containing Olmesartan Medoxomil (an ARB) and Hydrochlorothiazide (a thiazide diuretic). It was developed by Daiichi Sankyo and approved by the FDA in 2003. Generic versions have been available since 2016.
It's prescribed to treat high blood pressure when a single medication isn't enough. The combination of an ARB and a diuretic attacks high blood pressure from two directions: relaxing blood vessels and removing excess fluid. For a full overview, check out our post on what Benicar HCT is and how to use it.
As of March 2026, Benicar HCT and its generic equivalent (Olmesartan/Hydrochlorothiazide) are not listed on the FDA drug shortage database. This means there is no recognized nationwide supply disruption.
However, that doesn't mean you won't have trouble finding it. Here's why:
In other words, the drug exists and is being manufactured — but it might not be at your pharmacy right now.
Several factors contribute to intermittent availability issues:
Generic Olmesartan/HCTZ is manufactured by multiple companies, including Torrent Pharmaceuticals, Aurobindo, Macleods, and others. When any one manufacturer slows production — due to quality inspections, raw material shortages, or factory maintenance — it can create a temporary gap that other manufacturers may not immediately fill.
Chain pharmacies use automated systems to decide what to stock. If a location fills fewer than a handful of Benicar HCT prescriptions per month, the system may not keep it in inventory. This means even a common drug can feel hard to find at certain locations.
The generic drug market has seen consolidation over the past decade, with fewer manufacturers producing certain drugs. While Olmesartan/HCTZ still has multiple manufacturers, any reduction in competition can make supply less resilient.
For a deeper look at these issues, read our post on why Benicar HCT is hard to find.
Cost depends heavily on whether you're getting brand-name or generic, and whether you have insurance:
If cost is a barrier, we've put together a comprehensive guide on how to save money on Benicar HCT.
While no new brand-name ARB/HCTZ combinations have launched recently, the generic market continues to provide multiple options:
If you're considering a different medication in the same class, read our guide on alternatives to Benicar HCT.
If your pharmacy doesn't have it, here's what to do:
For a detailed walkthrough, see our post on how to find Benicar HCT in stock near you.
Benicar HCT is not in a national shortage in 2026 — but local supply issues can still make it feel that way. The generic version is widely manufactured, affordable with coupons ($15 or less), and covered by most insurance plans.
If you're having trouble finding it, Medfinder is the fastest way to locate a pharmacy with stock. And if availability continues to be an issue, talk to your doctor about the many effective alternatives in the same drug class.
Don't skip your blood pressure medication. With a little effort and the right tools, you can stay on track with your treatment.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.